Abstract
Background:
The aim of this study was to identify novel microRNAs for potential use in the diagnosis of pancreatic cancer (PaC).
Methods:
A total of 1063 serum samples from 303 patients with PaC were collected, and the expression level of miR-25 was measured using quantitative real-time PCR (qRT-PCR).
Results:
We found that miR-25 had significant diagnostic value for the differential diagnosis of PaC in normal controls with an AUC (the area under the ROC curve) of 0.915 (95% CI: 0.893-0.937) that was significantly higher compared with an AUC of 0.725 for serum tumor marker carcinoembryonic antigen (CEA) and an AUC of 0.844 for CA19-9.
Conclusions:
These data suggest that serum miR-25 has strong potential as a novel biomarker for the early detection of PaC.
© 2016 The Author(s) Published by S. Karger AG, Basel.
MeSH terms
-
Adult
-
Aged
-
Area Under Curve
-
Biomarkers, Tumor / blood*
-
Biomarkers, Tumor / genetics
-
CA-19-9 Antigen / blood
-
CA-19-9 Antigen / genetics
-
Carcinoembryonic Antigen / blood
-
Carcinoembryonic Antigen / genetics
-
Case-Control Studies
-
Diagnosis, Differential
-
Early Diagnosis
-
Female
-
Gastrointestinal Neoplasms / blood
-
Gastrointestinal Neoplasms / diagnosis*
-
Gastrointestinal Neoplasms / genetics
-
Gastrointestinal Neoplasms / pathology
-
Gene Expression
-
Humans
-
Male
-
MicroRNAs / blood*
-
MicroRNAs / genetics
-
Middle Aged
-
Neoplasm Staging
-
Pancreas / metabolism
-
Pancreas / pathology
-
Pancreatic Neoplasms / blood
-
Pancreatic Neoplasms / diagnosis*
-
Pancreatic Neoplasms / genetics
-
Pancreatic Neoplasms / pathology
-
Pancreatitis, Chronic / blood
-
Pancreatitis, Chronic / diagnosis*
-
Pancreatitis, Chronic / genetics
-
Pancreatitis, Chronic / pathology
-
ROC Curve
Substances
-
Biomarkers, Tumor
-
CA-19-9 Antigen
-
Carcinoembryonic Antigen
-
MIRN25 microRNA, human
-
MicroRNAs